신경조절 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Neuromodulation Devices Market Summary

The global neuromodulation devices market size was estimated at USD 6.37 billion in 2025 and is projected to reach USD 13.93 billion by 2033, growing at a CAGR of 10.35% from 2026 to 2033. The rising government funding for R&D activities in these devices, increasing prevalence of neurological disorders and technological advancements in these devices are driving the market growth.

For instance, according to the Parkinson's Foundation, around 1 million people are living with Parkinson's disease in the U.S., which is further expected to increase to 1.2 million by 2030. The incidence of neurological disorders is on the rise, leading to an increased need for innovative treatment solutions, including neuromodulation devices. For instance, according to the World Health Organization (WHO) in February 2024, around 5 million people are diagnosed with epilepsy, which is around 49 people per 100,000 population. Moreover, conditions such as Parkinson's disease, essential tremor, dystonia, and medically refractory epilepsy are increasingly being addressed through techniques such as Deep Brain Stimulation (DBS) and other implantable neurostimulation systems. Thus, the increasing prevalence of these conditions significantly increases the demand for advanced neuromodulation devices.

Technological advancements, particularly the continuous introduction of next-generation internal neuromodulation devices, are a major driving force behind the growth of the neuromodulation devices market. Innovations such as miniaturized implantable systems, closed-loop stimulation, AI-driven programming, and wireless or rechargeable platforms are significantly improving device precision, patient comfort, and long-term therapy outcomes. New product launches also expand clinical indications, enabling treatment of chronic pain, movement disorders, epilepsy, depression, and emerging neuropsychiatric conditions with greater efficacy. As companies introduce devices with longer battery life, personalized stimulation algorithms, and enhanced connectivity for remote monitoring, both clinicians and patients are adopting these solutions at a faster pace, supporting broader market expansion and accelerating the global shift toward advanced neuromodulation therapies.

Global Neuromodulation Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global neuromodulation devices market report on the basis of product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Spinal Cord Stimulators
• Deep Brain Stimulators
• Sacral Nerve Stimulators
• Vagus Nerve Stimulators
• Gastric Electrical Stimulation
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Parkinson's Disease
• Chronic Pain
• Migraine
• Epilepsy
• Tremor
• Depression
• Urinary & Faecal Incontinence
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Ambulatory Surgery Centers (ASC)
• Clinics & Physiotherapy Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Neuromodulation Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Government funding for research and development
    • 3.2.1.2. Technological advancements in neuromodulation devices
    • 3.2.1.3. Increasing prevalence of neurological disorders
    • 3.2.1.4. Growing reimbursement coverage
    • 3.2.1.5. Expanding applications
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Complex regulatory framework
    • 3.2.2.2. Surgery-associated risk
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Increasing number of clinical trials and studies
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Product recalls
    • 3.2.4.2. Alternatives to neuromodulation systems
• 3.3. Neuromodulation Devices Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Neuromodulation Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Neuromodulation Devices Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Neuromodulation Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Spinal Cord Stimulators
  • 4.4.1. Spinal cord stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Deep Brain Stimulators
  • 4.5.1. Deep brain stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Sacral Nerve Stimulators
  • 4.6.1. Sacral nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Vagus Nerve Stimulators
  • 4.7.1. Vagus nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Gastric Electrical Stimulation
  • 4.8.1. Gastric electrical stimulation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neuromodulation Devices Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Neuromodulation Devices Market: Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Neuromodulation Devices Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 5.4. Parkinson's Disease
  • 5.4.1. Parkinson's disease market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Chronic Pain
  • 5.5.1. Chronic pain market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Migraine
  • 5.6.1. Migraine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Epilepsy
  • 5.7.1. Epilepsy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Tremor
  • 5.8.1. Tremor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Depression
  • 5.9.1. Depression market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.10. Urinary & Fecal Incontinence
  • 5.10.1. Urinary & fecal incontinence market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neuromodulation Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Neuromodulation Devices Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Neuromodulation Devices Market Size & Trend Analysis, by End Use 2021 to 2033 (USD Million)
• 6.4. Hospitals & Ambulatory Surgery Centers (ASC)
  • 6.4.1. Hospitals & Ambulatory Surgery Centers (ASC) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Clinics & Physiotherapy Centers
  • 6.5.1. Clinics & physiotherapy centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neuromodulation Devices Market: Regional Estimates & Trend Analysis by Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait neuromodulation devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. Abbott (St. Jude Medical)
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Medtronic
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Boston Scientific Corporation
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Aleva Neurotherapeutics
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Nexstim
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. LivaNova PLC
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Neuropace Inc.
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Mainstay Medical
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Saluda Medical Pty Ltd
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Biotronik
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. electroCore, Inc.
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. MicroTransponder Inc.
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. tVNS Technologies GmbH
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Laborie
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives